Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Upper Respiratory Tract Infection Treatment Market Outlook

The global upper respiratory tract infection treatment market size attained a value of USD 1.81 billion in 2023. The market is likely to grow at a CAGR of 3.6% during the forecast period of 2024-2032. With this growth rate, the market is anticipated to attain a value of USD 2.48 billion by 2032.

Global Upper Respiratory Tract Infection Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Upper Respiratory Tract Infection Treatment Market: Introduction and Insights

An upper respiratory tract infection (URTI) is an illness, which is the result of an acute infection involving a person’s upper respiratory tract like the nose, sinuses, pharynx, or larynx. The infection commonly includes nasal obstruction, sore throat, tonsillitis, pharyngitis, laryngitis, otitis media, and the common cold. This can be treated using various drugs, targeting disease-causing pathogens like bacteria and viruses.

The signs and symptoms of the condition include fever, cough, runny nose, hoarse voice, fatigue, vomiting, unconsciousness, difficulty in breathing, retractions, especially in children, and stridor, among others. While the symptoms usually get better in one to two weeks, in some cases the condition might get worse if the symptoms do not subside within this timeline. In worst case scenario, the infection might lead to bronchitis or pneumonia.

Upper respiratory tract infection can affect anyone, but some people are more prone to the condition, especially children. Children are at a higher risk of catching the infection since the possibility of transmission is much higher. Children do no follow regular hygiene habits, like washing hands, and are more likely to carry the germs in their hands and put their fingers in their mouth, nose, and/or eyes, enabling the germs to enter the body. Other than children, people with lung or heart disorders are also vulnerable to the condition. Weak immune system also makes people more prone to upper respiratory tract infection.

Upper Respiratory Tract Infection Treatment Market Segmentations

The market can be categorised into segments like type, route of administration, distribution channel, and major regions.

Global Upper Respiratory Tract Infection Treatment Market Type

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Type

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) And Nasal Decongestants
  • Others

Market Breakup by Route of Administration

  • Oral
  • Nasal
  • Parenteral

Market by Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

Upper Respiratory Tract Infection Treatment Market Analysis

The growing incidence of upper respiratory tract infections, the development of new drugs, and the increasing demand for over-the-counter drugs is aiding the growth of the upper respiratory tract infection treatment market globally. With the advancement in technology and development in the treatment of upper respiratory tract infection, the market is witnessing an increased growth. Further, the growing awareness regarding the treatment and the rising disposable income, especially in emerging economies, are expected to drive the industry growth over the forecast period.

The antibiotics segment, among other types, dominated the global market in 2023, owing to its easy availability and effective results. Region-wise, while North America accounted for the highest share in the market in 2023, the Asia Pacific region is expected to grow at the fastest rate over the forecast period owing to the growing population and increased expenditure on health care services in the region.

Global Upper Respiratory Tract Infection Treatment Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

The report presents a detailed analysis of the following key players in the global upper respiratory tract infection treatment market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Cipla Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Alcon, Inc.
  • Teva Pharmaceuticals
  • Sandoz, Inc.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Route of Administration
  • Distribution Channel
  • Region
Breakup by Type
  • Antibiotics
  • Nonsteroidal Anti-Inflammatory Drugs (Nsaids) And Nasal Decongestants
  • Others
Breakup by Route of Administration
  • Oral
  • Nasal
  • Parenteral
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Cipla Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Alcon, Inc.
  • Teva Pharmaceuticals
  • Sandoz, Inc.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

Upper Respiratory Tract Infection Treatment Market Report Snapshots

Upper Respiratory Tract Infection Treatment Market Size

Upper Respiratory Tract Infection Treatment Market Analysis

Upper Respiratory Tract Infection Treatment Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!

Key Questions Answered in the Report

The market size attained a value of USD 1.81 billion in 2023, driven by the rising prevalence of lung disorders.

The market is likely to grow at a CAGR of 3.6% during the forecast period of 2024-2032 to attain a value of USD 2.48 billion by 2032.

The major drivers of the market include the growing incidence of upper respiratory tract infections, development of new drugs, growing awareness regarding the treatment, rising disposable income, and advancement in technology.

They key trends in the market include the rise in the demand for and availability of over-the-counter drugs, and the advent of biologics.

The major regional markets include North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

The types can be divided into nonsteroidal anti-inflammatory drugs (NSAIDs) And nasal decongestants, among others.

The routes of administration include oral, nasal, and parenteral routes.

The distribution channels in the market include hospital pharmacies and online pharmacies, among others.

The key players in the market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc., Cipla Limited, Lupin Limited, Merck & Co., Inc., Alcon, Inc., Teva Pharmaceuticals, and Sandoz, Inc., among others.

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Pricing Plans

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Strategic Solutions for Informed Decision-Making

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124